Study of Drug Delivery Using Purely Organic Macrocyclic Containers—Cucurbit[7]uril and Pillararene Authors: Arnab Roy Chowdhury, Soumyabrata Goswami Published: 2023 ABSTRACT AbstractAn impaired immune system is the root of various human ailments provoking the urge to find vehicle-mediated quick delivery of small drug molecules and other vital metabolites to specific tissues and organs. Thus, drug delivery strategies are in need of improvement in therapeutic efficacy. It can be achieved only by increasing the drug-loading capacity, increasing the sustained release of a drug to its target site, easy relocation of drug molecules associated with facile complexation-induced properties of molecular vehicles, and high stimuli-responsive drug administration. Supramolecular drug delivery systems (SDDS) provide a much needed robust yet facile platform for fabricating innovative drug nanocarriers assembled by thermodynamically noncovalent interaction with the tunable framework and above-mentioned properties. Measures of cytotoxicity and biocompatibility are the two main criteria that lie at the root of any promising medicinal applications. This Review features significant advancements in (i) supramolecular host–guest complexation using cucurbit[7]uril (CB[7]), (ii) encapsulation of the drug and its delivery application tailored for CB[7], (iii) self-assembly of supramolecular amphiphiles, (iv) supramolecular guest relay using host–protein nanocavities, (v) pillararene (a unique macrocyclic host)-mediated SDDS for the delivery of smart nanodrugs for siRNA, fluorescent molecules, and insulin for juvenile diabetes. Furthermore, fundamental questions and future hurdles related to smart SDDS based on CB[7] and pillararenes and their future promising breakthrough implementations are also distinctly outlined in this Review. Introduction Supramolecular chemistry, as elucidated by one of its eminent proponents, Jean Marie Lehn, as “chemistry beyond molecules”, has been identified as an incredible approach in biomedical applications having immense potential for diagnosis and therapeutic treatment with the reason rooted in their hydrophobic cavity and their controllable components.1 Supramolecular nanodrug carriers are developed by several noncovalent interactions like hydrophobic interaction, electrostatic attraction, hydrogen bonding, π–π interactivity, etc. These nanodrug carriers have been placed in frontiers of recent research due to their acute potential for artificial modification and firm encapsulation. They have reasonable binding constants to reduce the tendency of guests to undergo unwanted aggregation, thus leading to diversification of drug delivery systems. The synergy between various organic guest molecules and the water-soluble macrocyclic host molecules are prototype illustrations of supramolecular interactions.2 Reversibility of host–guest complexation is an essential criterion for partial or complete retention of therapeutic activity of encapsulated drugs.1−9 Cucurbit[n]urils (CB[n], n = 5–10) are a novel category of barrel-shaped water-soluble cyclic oligomers, composed of “n” number of glycoluril units laced by two methylene groups (Figure 1).10−12 CB[n] is a rigid hydrophobic container having two symmetrical orifices composed of n carbonyl units, which assists it to bind molecules bearing positive charges or cations firmly. Interestingly, the neutral and the hydrophobic guest molecules can also be housed inside the nonpolarizable and hydrophobic CB[n] cavity.13,14 In fact, important drug molecules can mimic these incorporated guest molecules necessary for advanced drug delivery applications,15−17 or it can be an optically active fluorescent dye for sensing applications18−20 or a polymeric guest for scaffolding smart nanomaterials.21−23 Along this line of research, several other macrocyclic containers have also been developed and were drawn to the fields of interest like cyclodextrin,24−29 calixarene,30,31 metallostructures,32−34 etc. There are certain properties that make CB[n] stand out in particular, which are their low cellular toxicity,37 high stabilization of incorporated drugs,4−7 high binding constant for cationic guests,35−38 effective shifting of the pKa of encapsulated guests,36,39−41 and supramolecular catalysis of hydrolytic reaction.42 Illustration showing the chemical structure of cucurbit[7]uril (CB[7], 1). Pillararenes (PA[n]), another emerging novel family of macrocyclic cavity bearing host molecules, were first synthesized and coined by Tomoki Ogoshi in 2008.43 Their unique pillar-shaped structure and simplistic functionalization have received burgeoning attention because they endow them with distinct capabilities to selectively bind various kinds of important guests.44 Pillararenes paved well their way toward application of nanomaterial,45−47 molecular recognition,48−51 chemosensors,52−54 ion transport,55 supramolecular polymers,56,57 transmembrane channels,58 light-harvesting systems,59,60 nonporous adaptive crystals,61,62 and hydrogels.63 Water-soluble pillararenes not only exhibit excellent biocompatibility and low pH-sensitive properties in aqueous media but also show strong binding ability for different types of guest molecules. PA[n]’s hydrophobic cavities are quite adaptive (n = 5–10), fetching enough scope not only to augment the host–guest complexation but also to develop more types of supra-amphiphiles including head-to-tail tadpole-like, bola-type, gemini-type, macrocyclic, and polymeric amphiphiles. Higher-order aggregates like vesicles, micelles, or nanoparticles can be achieved for controllable anticancer drug delivery64 by tuning pillararene-based amphiphilic supramolecular host–guest complexes in such a way that they can even further self-assemble to form the desired drug-loading vehicle. In the line with the fascinating research on host–guest properties, it is highly well-timed to develop stimuli-responsive polymersomes self-assembled from PA[n]s-based supramolecular block copolymers as targeting SDDS for effective anticancer therapy.65 Pillararene-based supramolecular nanocarriers for effective chemo-photodynamic dual therapy are also examined in this Review. Cucurbit[7]uril (CB[7], 1) SDDS Formed by CB[7]-Encapsulating Benzimidazole-Derived Drugs In recent research studies, it has been revealed that benzimidazole (BZ, 2) residue has a great affinity for CB[7].9,66,67 Photophysical properties, photochemical stabilities, and aqueous solubilities of several BZ residues like albendazole (ABZ, 3), carbendazim (CBZ, 4), fuberidazole (FBZ, 5), thiabendazole (TBZ, 6) (Scheme 1), and their mother compound benzimidazole (BZ) with CB[7] are thoroughly investigated using UV–vis and NMR spectroscopy techniques, which reveal that CB[7] binds and stabilizes the protonated form of the above-mentioned anthelmintic drugs of the BZ family in water very robustly (e.g., K = 2.6 × 107 mol–1 L for ABZ) but encapsulates their unprotonated forms very feebly (e.g., K = 6.5 × 104 mol–1 L for ABZ),68 which signifies increase in pKa value upon complexation with CB[7]. In water ABZ, TBZ, CBZ, FBZ, and BZ showed far UV absorption of <320 nm and fluorescence in the region of 290–360 nm at pH 7.2, but at lower pH values, the absorption spectra undergo slight but distinct shift due to protonation of the benzimidazole residue. The change in the optical density (OD) at the peak maximum of the absorption spectra of BZ residues like ABZ, TBZ, CBZ, and FBZ is observed in the absence and presence of CB[7] at various pH values (Figure 2). UV titration was done to determine the host–guest binding constant (Table 1). CB[7], being a cation receptor, shows a consistently more significant binding constant with the protonated guest molecules than the neutral forms (ca. 2 orders of magnitude larger). Chemical Structures of the Benzimidazole Molecule and Its Derivatives pH titration plots of the BZ drugs, tracked by UV in the absence (filled circles) and presence of CB[7] (2.5 mmol L–1, empty circles).68 Reprinted with permission from ref (68). Copyright 2022, Canadian Science Publishing. Table 1pKa Values of Uncomplexed (pKa) and the CB[7]-Complexed Form (pKa′) of BZ Derivatives in Water68,aguestpKapKa′ΔpKaKBZ (103 mol–1 L)KBZH+ (103 mol–1 L)ABZ3.56.12.66526CBZ4.57.02.52476TBZ4.68.64.00.150 ± 0.0251.5FBZ4.88.63.80.05 ± 0.010.32BZ5.59.03.51.54.7aReproduced with permission from ref (68). Copyright 2011, Canadian Science Publishing. pKa Values of Uncomplexed (pKa) and the CB[7]-Complexed Form (pKa′) of BZ Derivatives in Water68,a Reproduced with permission from ref (68). Copyright 2011, Canadian Science Publishing. To investigate the structural features of these host–guest-complexed drug molecules, 1H NMR study was performed only to realize that during the complexation of FBZ in D2O at pH 2 the imidazolium protons are upfield shifted when complexed with CB[7] of up to 1 ppm. In contrast, the furanyl protons are either barely affected or even undergo downfield shift (Figure 3). 1H NMR-based spectral plot of 0.25 mmol L–1 FBZ (a) in the absence of CB[7] and (b) in the presence of 2.5 mmol L–1 CB[7] in D2O at pD 2.4.68 Reprinted with permission from ref (68). Copyright 2011, Canadian Science Publishing. The same observations are reported for other BZ residues also, which reflects preferential inclusion of the imidazolium moiety of BZ residue inside the CB[7] cavity while the furanyl ring is protruded out near the rim. Similarly, for ABZ, the hydrophobic propylthio moiety is the only one adequately encapsulated inside the CB[7] macrocycle, proved by its upfield shifts. To further delve into this observation, a negative control experiment was conducted in which a smaller macrocycle, CB[6], was taken instead of CB[7], which showed that it could not encapsulate the BZ ring due to its smaller cavity but can only encapsulate the other smaller groups of the BZ residues like carbamate methyl groups of ABZ and CBZ (upfield shift of 1 ppm). The carbonyl portal of CB[7] gives an additional stabilization of the protonated form of these guest molecules by dint of the ion–dipole interaction. The guest molecule is easily protonated when it is complexed with CB[7], which is reflected in the experimental data of larger pKa shift in the case of complex formation with CB[7]. Though these benzimidazole-derived drugs are extensively used as fungicide and anthelmintic drugs,33,69−74 their only common drawback is their poor aqueous solubility, which is very unacceptable as a feature of anthelmintic drugs. So, to overcome this drawback, CB[7], a potential additive, is used for the solubility enhancement. Interestingly, by adding only 2 mmol L–1 of CB[7], the solubility of ABZ, CBZ, TBZ, and FBZ can be enhanced by a factor of 100, 7, 10, and 3, respectively (Figure 4). Thus, the CB[7] macrocycle acts as a promising candidate for drug solubilization of these types of least soluble drugs. The photostability of TBZ and FBZ is enhanced by CB[7] encapsulation, with the result that FBZ decays 7 times slower and TBZ 3 times slower when complexed by CB[7] than their free states. For the rest of the drug molecules, the photostability effect is not so significant. At pH 7.2, absorption spectra measured for the BZ drugs in the absence (dashed lines) and presence of CB[7] (2.0 mmol L–1, solid lines). The arrows show the enhancement of the solubility factors. Note that the solution taken for UV spectroscopic analysis is 30 times diluted in order to obtain an OD value inside the instrumental range.68 Reprinted with permission from ref (68). Copyright 2011, Canadian Science Publishing. These types of prospective applications of cucurbituril are also exhibited by β-cyclodextrin but of lower efficiency because a very high concentration of β-cyclodextrin is required to compete with that of cucurbituril. This can be due to the lower binding constant of β-cyclodextrin and its inability to induce protonation. Thus, cucurbituril wins the spotlight of being the most unique and novel futuristic drug carrier. SDDS Formed by CB[7]-Encapsulating Neurotransmitter Hormone Serotonin (7) Serotonin (7) or 5-hydroxytryptamine (Figure 5a) is a naturally occurring monoamine neurotransmitter for the central and peripheral nervous system. It is a multifaceted key hormone responsible for mood modulation like sleep, addiction, cognition, learning, memory, aggression, food intake, nausea, and anxiety widely formed in the brain by the serotonergic neurons. Serotonin (SRT, 7) was first discovered by Vittorio Erspamer, an Italian pharmacologist, in 1952,75 and later Walther et al. synthesized it by a second tryptophan hydroxylase isoform in 2003.76 Sudden imbalance of the serotonin level in the body can cause serious mental disorders like Alzheimer’s disease, schizophrenia, infantile autism, and depression as stated by Dubovsky and Thomas in 1995 and Voet and Voet in 2006.77 SRT was reported to exhibit different fluorescence properties by Kishi et al. in 1977.78 SRT has primarily two pKa values, one at 9.97 for an aliphatic amino group and one at 10.73 for an aromatic hydroxyl group (Figure 5B). Considering the acute diseases caused by the disorder of the SRT level in our body, the delivery of SRT is essential through the supramolecular drug delivery system for effective therapy against various SRT syndromes. Thus, for the encapsulation of such a hydrophobic guest molecule, a rigid and hydrophobic macrocyclic molecule is required, and CB[n] was chosen for this vehicular purpose. This is so because the encapsulation led to a significant shift in pKa value, enhancement of the solubility factor of the drug molecule, sustained release of drug, and sensing via electronic spectroscopy for an optically active molecule.79 Upon CB[7] encapsulation SRT exhibited pH-dependent binding affinity. (A) Diagram showing chemical structure of serotonin (SRT, 7) (B) Prototropic equilibrium of SRT with different pH values. The photolytic activity of SRT is very much pH sensitive to the surrounding solution. In low pH, two absorption maxima, one at 277 nm and another at 297 nm, are exhibited by SRT, while at basic pH, the 297 nm band gets quenched and the band with maximum at 325 nm gets developed (Figure 6), leading to a bathochromic shift due to an increase in the resonance of the chromophoric unit. This phenomenon happens due to the deprotonated phenolic −OH group of the indole ring, and as a result, the phenolate ion undergoes ring resonance. The transition between the unprotonated and the protonated form is aptly denoted by the isosbestic point at 309 nm. Upon exciting at 280 nm at different pH values by fluorescence spectroscopy, it was observed that the intensity tends to be negligible with increasing pH. This observation can be explained by the poor absorbance value of the ionized species at the excitation wavelength, which is followed by the continuous weakening of the intensity above the physiological pH. The reported acid dissociation constant of the primary amine of SRT is 9.9. The pKa values gathered from the pH titration using absorption and emission spectroscopy are the same. This signifies that no alteration is observed in the pKa value upon electronic excitation. UV–vis titration of 5 μM SRT at pH 3.0 with a gradual increment in the concentration of the CB[7] resulted in an isosbestic point at 280 nm reflecting the perfect encapsulation of SRT in the CB[7] macrocycle. To get additional evidence of encapsulation, fluorescence titration was performed again with increasing concentration of CB[7] along with 10 μM SRT at pH 3. (A) UV–vis-based pH titration graph showing the surge of the 333 nm absorption peak with increasing pH, (B) fluorescence-based pH titration graph illustrating the quenching of the fluorescence peak at 335 nm with pH, and (C) determination of the pKa value from UV–vis and fluorescence titration. The normalized optical density at 333 nm and the fluorescence intensity at 335 nm are plotted against the pH of the solution.79 Reprinted from ref (79). Copyright 2020, Frontiers. Upon increasing the amount of CB[7], the fluorescence intensity progressively gets quenched, and saturation was only obtained after the incorporation of 1.5 mM CB[7] (Figure 7A). Thus, the attenuation of fluorescence intensity signifies a strong host–guest encapsulation. To determine the rotational restriction experienced by the SRT molecule in the macrocyclic cavity of the CB[7], time-resolved anisotropy decay measurement was done at acidic pH (pH ∼ 3.0), which fetched the result that the anisotropy of SRT got a surge from 0.2 to 0.6 ns upon treatment with CB[7] (Figure 7B). The higher anisotropy value of SRT in the presence of CB[7] at acidic pH signifies the restriction of free rotation posed by the hydrophobic cavity of CB[7]. (A) Fluorescence titration of SRT with CB[7] at pH 3.0; encapsulation leading to a gradual decrease of the intensity peak, and (B) time-resolved anisotropy decay plot of SRT in the presence and absence of CB[7] at pH 3.79 Reprinted from ref (79). Copyright 2020, Frontiers. At higher pH, no change in anisotropy is observed due to feeble complexation. To find out the complexation-induced shift (CIS), NMR study was performed. At acidic pH (pD 3.0), an intense upfield CIS was observed for Hb, Hc, and Hf, which bears evidence that those hydrogen atoms of SRT are rooted inside the cavity of the CB[7] (Figure 8). Conversely, a small upfield CIS for Ha, Hd, and He signifies that these protons are present relatively nearby to the rim of the CB[7]. With the intention to check the stability and the depth of the inclusion complex SRT·CB[7], competition titration was done with cesium. At first, Cs+ binds to the mouth of CB[7], and then, by reorienting SRT, it forms a ternary complex SRT·CB[7]·Cs+ (Figure 9) where Cs+ forms a lid to one side of CB[7], which was further validated by fluorescence titration. Thus, the path for SRT delivery is promisingly paved by CB[7], considering it to be a very significant neurotransmitter. (A) NMR titration plot of 0.5 mM SRT with increasing concentration of CB[7] up to 4.0 mM at pD 2.8; the aromatic region and the aliphatic region are illustrated in the left zone and the right zone of the NMR titration plot, respectively, (B) fitted plot of the variation in complexation-induced shift (CIS) against the concentration of CB[7], and (C) pictorial representation of the feasible SRTH+·CB[7] complex.79 Reprinted from ref (79). Copyright 2020, Frontiers. (A) NMR titration plot of the SRT·CB[7] (0.5 mM SRT) complex with increasing concentration of CsCl up to 10 mM at pD 2.5; left portion shows the aromatic region and the right portion shows the aliphatic region of the NMR spectra. (B) A fitted plot illustrating the difference in chemical shift values (in ppm) against the concentration of CsCl. (C) Diagrammatic illustration of the SRT·CB[7]·Cs+ complex.79 Reprinted from ref (79). Copyright 2020, Frontiers. Encapsulation of Norharmane Drug (8) by CB[7] Norharmane (NHM, 8), a β-carboline-based drug, is a nitrogen-containing heterocycle that commonly acts as a GABA (gamma-aminobutyric acid) agonist (Figure 10). It is an active alkaloid which has an anxiogenic and memory-enhancing effect. It is composed of a π-electron-rich indole ring and a π-electron-deficient pyridine ring.80,81 Pharmacologically, it is a type of hallucinogen which has antitumor activity. It is also produced endogenously from the human body82 as well as being a photoproduct from tryptophan in the human eye lens.80−82 Recently, it has been used as photosensitizers for virus, bacteria, and fungi with a remarkable DNA binding constant,83,84 but like other drugs mentioned above, it also faces the same drawback of poor water solubility. Its solubility can be enhanced if it is provided with an amphipolar and microheterogeneous cavity. The micellar environment provided by the well-organized assemblies of surface-active agents or macrocyclic containers does have a massive impact on the bioavailability,85 photophysical, and chemical properties of these β-carboline-based sparingly water-soluble drugs. The hydrophobic nanocavity of the caged macrocycles, just like biological organization, encapsulates drug molecules with high binding affinity.86 In the last few decades, CB[n] and acyclic type CB have been used extensively as a drug delivery vehicle for sparingly water-soluble drugs.35,66,68,87,88 The factors by which incorporation of CB[7] can enhance the solubility of the sparingly soluble drugs at neutral pH have been compiled in Table 2. Structure of norharmane (NHM, 8) and the protolytic equilibrium between its neutral and protonated forms (NHMH+). Table 2Solubility Improvement Factor of Poorly Soluble Drugs Using CB[7] at Neutral pH89,adrugs categorydrugsolubility enhancement with CB[7] (pH 7.0)anthelmintic drugsbenzimidazole2fuberidazole3carbendazim7photosensitizernorharmane12testosterone5progesterone21anticancer drugcamptothecin70gefit inib102antileprosyclofazimine63aReproduced with permission from Ref (89). Copyright 2018, Elsevier. Solubility Improvement Factor of Poorly Soluble Drugs Using CB[7] at Neutral pH89,a Reproduced with permission from Ref (89). Copyright 2018, Elsevier. As the stability of the self-aggregated micelles depends upon factors like pH, temperature, viscosity, and ionic strength, it is not suited for drug delivery applications. At near-neutral pH value of NHM, the CB[7] nanocavity can modulate its optical properties. To estimate the binding interaction of NHM with CB[7], fluorescence binding titration was performed using 6 μM NHM with increasing concentration of CB[7] macrocycle at pH 3. The 450 nm band (Figure 11) was seen to be attenuated along with a 5 nm hypsochromic shift. This phenomenon strongly relates hard-core binding of NHMH+ with CB[7] at acidic pH. Excited-state pH titration plot of NHM.89 Reprinted with permission from ref (89). Copyright 2018, Elsevier. NHMH+ experiences preferential stabilization in CB[7] over neutral ones, which is evident from the similar titration performed with neutral NHM that showed less average lifetime of NHM than NHMH+ in CB[7]. For further exploration of the effect of encapsulation phenomena on excited-state lifetime and anisotropy decay of NHM in different types of microenvironments, time-resolved fluorescence spectroscopy was performed, which showed that at acidic pH, NHMH+ had a fluorescence lifetime of only 22.0 ns when decay was at 450 nm. The fluorescence decay graph is a biexponential decay type along with a longer lifespan and shorter component. The two different lifetime components in the fluorescence decay signify that both the neutral and the protonated species are in equilibrium. For investigation of solubility enhancement of the drug molecule by CB[7], UV–vis spectroscopy is conducted only to find that the solubility of NHM is enhanced by a factor of 14.0, 12.0, and 9.0 at low (pH 3.0), physiological (pH ∼ 7.0), and high pH (pH 12.1), respectively, upon the incorporation of 4.0 mM CB[7] (Figure 12). Such solubility enhancement is a much-needed requirement for the poorly soluble β-carboline-based drugs. The NHM·CB[7] complex showed an increased cellular uptake compared to that of the free species when both were incubated with MCF-7 cells, evident from the high-intensity fluorescence from NHM entering the nucleus via CB[7]. Thus, CB[7] showed a ray of light for the NHM drug to be used on a wider scale without looking at any major hindrances or restrictions related to its delivery process inside our biological system. Absorption spectra plot of free NHM in the absence of CB[7] (dashed lines) and the presence of 4.0 mM CB[7] (solid line) at (a) pH 3.0, (b) pH 6.8, and (c) pH 12.1. (d) Bar-diagram illustrating the following solubility enhancement factor with CB[7]. The error bar shows the standard deviation from triplicated measurements.89 Reprinted with permission from ref (89). Copyright 2018, Elsevier. Activation and Stabilization of Proton Pump Inhibitor Drugs by Cucurbituril Encapsulation of drugs by CB[7] manifests a shift in the excited-state protonation equilibrium.90 Pluth et al. recently demonstrated an interesting example of pKa shift with the metal–organic supramolecular host having values extending up to 4.5.91 Proton pump inhibitor drugs are a category of medications which are used for reducing prolonged stomach acid production which can lead to gastroesophageal reflux along with duodenal ulcers. They inhibit the stomach’s H+/K+ ATPase irreversibly. Lansoprazole (9a) and omeprazole (9b) (Scheme 2) are two examples of proton inhibitor drugs administered orally. The major drawbacks of these types of drugs are (i) prolonged conversion into cyclic sulfenamide (9c) as this active species can only react with the cysteine residues of the stomach’s H+/K+ ATPase and (ii) rapid dimerization and decay of the active state in a very short time when exposed to highly acidic pH of the stomach. Lansoprazole (9a) and Omeprazole (9b) So, to overcome these drawbacks the addition of CB[7] can be a way out as it helps in activation and stabilization. CB[7] not only catalyzes the formation of the active form of the drug (9c) but also enhances the stability of the cyclic sulfonamide (9c). UV spectroscopy is done to follow the kinetics of activation and disintegration of the drug (Figure 13). The UV absorption maxima at 340 nm (Figure 13 inset) signifies the active form. An increase in rate was observed from 0.2 to 3 min–1 which reveals that the half-life period of formation was reduced from 5 min to 20 s upon the addition of CB[7] (0.05–5 mM). Upon adding CB[7] (5 mM), the half-life of the active species increased from 60 min to more than 3 weeks at pH 2.9. Moreover, in the presence of CB[7] the reactive intermediate exhibits a nice and clean 1H NMR spectrum in D2O (Figure 14). Omeprazole also exhibited a similar type of favorable effect upon encapsulation by CB[7]. To validate the inclusion of a proton pump inhibitor with CB[7], a competitive experiment was done with cadaverine (pentane-1,5-diamine). Cadaverine forms a strong inclusion complex with CB[7], thus dislodging the omeprazole from the cavity into free solution where it undergoes rapid decomposition (half-life 60 min). However, unfortunately, direct determination of the binding constant and the pKa shift was not possible due to the lability of both free species in aqueous solution. CB[7] helps in tuning of protonation equilibrium, thus aiding in rapid activation, but this strategy is somewhat unconventional because during supramolecular pKa shift, along with increasing the basicity of the benzimidazole group, it also affects the nucleophilicity and the basicity of the pyridine moiety on a smaller scale. Upon dissolving 9a (50 mm) in aqueous solution at pH 2.9, the active form evolved followed by UV spectroscopy (λmax = 340 nm) in the absence (dashed line) and presence (solid) of 0.2 mm CB[7]. The inset plot shows the UV spectra of 9a (dashed line, straightaway after dissolution in the absence of CB[7], λmax = 287 nm) and of the complex 9c·CB[7] (solid line, with 1 mm CB[7] after 3 min, λmax = 340 nm).66 Reprinted with permission from ref (66). Copyright 2008, Wiley-VCH. 1H NMR-based spectra of the aromatic region recorded in D2O of (a) the 9a·CB[7] complex (2 mm 1a, 5 mm CB7) at pD 3.3 and (b) the disulfide adduct 3a obtained in situ from the 9a·CB[7] complex (0.75 mm 1a, 3 mm CB[7]) upon adding 2.0 mm cysteine.66 Reprinted with permission from ref (66). Copyright 2008. Wiley-VCH. Encapsulation of a Platinum Anticancer Drug by CB[7] Among several platinum anticancer drug complexes, cisplatin (10a) (Figure 15a) is a highly competent drug for the treatment of human neck, head, bladder, lungs, testicular, as well as ovarian cancer.92 Despite its high effectiveness in cancer treatment, its prolonged use can be hindered by some of its acquired and innate restrictions.93 Such factors are low cellular uptake, deactivation of the drug by increase in the body’s glutathione level, or increase of the tolerance level of DNA lesions against such platinum-based drugs.94 Moreover, cisplatin is also accompanied by several side effects like nausea and nephro- and neurotoxicity which has certainly limited its dose level between 60 and 120 mg m–2.95 Due to such complexities, several other platinum-based drugs are approved like carboplatin and oxaliplatin, and many multinuclear platinum complexes are also simultaneously being developed. Multinuclear platinum-based complexes are expected to overcome the limitations through novel DNA-binding linkages. Unlike cisplatin and carboplatin, the multinuclear complexes generally form pliable and long-range interstrand adducts which can be easily taken up by the biological cells more than cisplatin. BBR3464 (10b) (Figure 15b) is among one such complex which has potentially made its entry in phase II clinical trials, and BBR3571, BBR3610, and BBr3611 have also showed immense capability in this field.94,96−99 Structures elucidating cisplatin (a), a common multinuclear platinum-based complex conjoined with a ligand, BBR3464 (b), di-Pt (c), and tri-Pt (d). Though these complexes require very low concentration for their activation compared to cisplatin, their toxicity levels are very high. Moreover, these complexes can be deactivated by the body’s plasma proteins before reaching their targets thus showing low activity. Thus, to curb their toxicity and easy degradation, cucurbiturils can be chosen as an effective host for the delivery of platinum-based multinuclear complexes. The complexation of trans-[{PtCl(NH3)2μ-dpzm]2+ (dpzm = 4,4′-dipyrazolylmethane) with CB[7] reduces the rate of reaction of platinum complex with guanosine without changing its usual DNA-binding mode.100 In the case of complexation of oxaliplatin with CB[7], its reactivity is reduced for both guanosine and methionine along with the lowering of in vitro cytotoxicity. NMR study was done in each case of complexation of CB[7] with cisplatin, di-Pt (10c), and tri-Pt (10d) (Figure 15c and 15d).101 The study of the interaction between cisplatin and CB[7] was done by 1H and 195Pt NMR.101 Upon adding cisplatin, the CB[7]-CH resonance at 5.58 ppm bifurcates into two peaks, 5.63 and 5.55 ppm (Figure 16a and 16b).101 One peak is upfield shifted and is characterized by significant line broadening, while the other peak is comparatively sharp and downfield shifted.101 1H NMR spectra elucidating (a) CB[7] added with cisplatin at R = 1 at 25 °C in D2O solvent, (b) CB[7], (c) di-Pt, and (d) di-Pt encapsulated with CB[7] at R = 1.101 Reprinted with permission from ref (101). Copyright 2006. The Royal Society of Chemistry. A similar characteristic is also observed for the peaks of the nonequivalent CB[7]-CH2 protons. When the platinum complex is dissolved in slightly acidic water, an equilibrium is established between the chloro- and hydrated-forms of cisplatin, with the peak of Pt for cis-[PtCl2(NH3)2] and cis-[PtCl(NH3)2(H2O)]+ at −2160 and −1854 ppm, respectively.101 When CB[7] was added, the chloro form exhibited a second resonance at −2109 ppm, while the peak for the aqua form was majorly shifted to −1890 ppm.101 Separate peaks for uncomplexed and complexed chloro forms signify reduced exchange kinetics, thereby revealing that a part of the chloro form gets firmly encapsulated inside the CB[7] cavity. A large upfield shift of the dpzm resonances was observed when di-Pt was encapsulated in CB[8], with the di-Pt H3 and methylene peak shifting to the same extent as that for CB[7] encapsulation.101 The H5 peak shifted upfield by only 0.94 ppm more than that in the case of CB[7] complexation (Figure 16c and 16d) which shows that the platinum-based complex is placed slightly differently in CB[8] than in CB[7].101 Moreover, the resonance due to the ammine protons of di-Pt shifted downfield with CB[7] encapsulation and shifted upfield upon CB[8] encapsulation which reveals that the −NH protons are situated deep inside the cavity of CB[8], unlike CB[7]. The dpzm peak of the CB[8] complexed with di-Pt is broader than that for CB[7] encapsulation which suggests that the transition rate between the CB[8] complexed di-Pt and the uncomplexed one is more rapid than for CB[7] encapsulation.101 This inference suggests that the rate of release and the toxicity of the Pt-based multinuclear drug can be tuned by the cavity size of CB[n] itself. From the 1H NMR study, it is observed that the hydrolyzed di-Pt requires more time (ca. 24 h) to be encapsulated by CB[7] than the unhydrolyzed one which is evident from the large upfield shift in the dpzm resonance of the aqua di-Pt complex.101 This same inference can also be derived for the tri-Pt complex as a very high energy is required for the +2-platinum center to get into the CB[n] portal. The encapsulation of tri-Pt is slightly different for CB[7] and CB[8] with distinguishable binding orientation, and additionally CB[n] is positioned nearer to one Pt center than the other two during the complexation. Thus, all such encapsulation of Pt-based anticancer drugs by CB[n] is supported by its (i) hydrophobic cavity and (ii) carbonyl portals which sterically protect them from unnecessary deactivations by biological nucleophiles in our body. Molecular modeling of the complexation of CB[7] with di-Pt (Figure 17) and tri-Pt revealed that they are deeply seated inside the hydrophobic cavity instead of attaching with the portal.101 Moreover, a slight distortion in CB[n] was also observed during the complexation with Pt-based drugs, but the optimal geometry was symmetrical with the methylene protons of dpzm located at the core of CB[n]. The center of the cavity of CB[n] was concluded to be the zone of maximum shielding, but as soon as the protons are placed near the walls or the portals a slight upfield shift is observed. Molecular model illustrating the perfect host–guest encapsulation between di-Pt and CB[7]: (a) top view and (b) side view.101 Reprinted with permission from ref (101). Copyright 2006. The Royal Society of Chemistry. Host–Guest Encapsulation of Histamine Type 2-Receptor Antagonist Ranitidine (11) and CB[7] Improvement of a smart drug delivery system using CB[7] for the delivery of several drug moieties has truly become the thrust field of research in the pharmaceutical chemistry owing to its excellent host guest encapsulation capability. Ranitidine hydrochloride (N,N-dimethyl-5-[2-(1-methylamino-2-nitrovinylamino) ethylthiomethyl] furfuryl-amine hydrochloride (RH+) (Figure 18a) is one such molecule which acts as a histamine H2 receptor antagonist to inhibit the excess production of stomach acid which can inevitably cause peptic ulcers and other diseases as well.102,103 Using UV–visible spectroscopy, it is observed that incorporation of CB[7] into the ranitidine solution at pH 2.5 has led to a decrease in the peaks at 228 and 313 nm (for furanyl protons and nitroethylenediamine chromophores respectively) until a 1:1 host–guest ratio.104 (a) Structure of monoprotonated ranitidine (Z isomer) along with the CIS value of its protons at pD = 2 denoted in red and (b) equilibria showing host–guest encapsulation and acid dissociation of ranitidine complexed with CB[7] in aqueous environment.104 (c) 1H NMR graph showing the resonances of deprotonated ranitidine without (bottom) and with 0.7 equiv (middle) and 1.4 equiv (top) of CB[7] at pD = 2 in D2O. The prime numbers shown in the top spectrum indicate the proton resonances for the E isomer.104 Reprinted with permission from ref (104). Copyright 2008. The Royal Society of Chemistry. The uncomplexed ranitidine forms a monocationic species in neutral environment with a protonated terminal dimethylamino group.104 Low pH induces the diamino vinyl group to get protonated for which the pKa1 value for the diprotonated ranitidine (RH22+) has been observed as 1.95 ± 0.01,105 2.19 ± 0.04,106 and 2.3 (ref (12)). The pKa2 values to form the neutral guest are shown as 8.13 ± 0.05,105 8.20 (12), and 8.35 ± 0.01.107 Such pKa values of the encapsulated protonated guest molecules can be tuned through ion dipole–dipole interactions with the polar carbonyl-rimmed portals. UV pH titration monitored the alteration in the absorbance value at 228 and 308 nm at pH range 1–6 during the encapsulation of RH22+.104 When {RH·CB[7]}+ was titrated with base at pH 8–12, a rise in the peak at 228 nm was reported, inferring release of the guest during deprotonation.104 pH-dependent UV spectral changes reported the value of pKa2 of CB[7] to be 9.8 ± 0.2.104 The electrospray ionization mass spectrum of a blend of ranitidine hydrochloride and CB[7] in aqueous environment showed peaks at m/z = 740 and 1478, with masses and molecular ion patterns congruous with {RH2·CB[7]}2+ and {RH·CB[7]}+, respectively.104 In the 1H NMR spectra (Figure 18c) the complexation-induced shift (CIS) values revealed that the central part of ranitidine is deeply seated inside the CB[7] cavity whereas the charged and neutral portions are positioned near the carbonyl-laced portals. Moreover, the CIS values of ca. 1.0 in the locus of the CH2–S–CH2CH2– central linker present in the drug molecule also explain that the sulfur atom is well encapsulated inside the quadrupolar CB[7] cavity which induces the sulfur atom to be directly engaged in dipolar–quadrupolar interaction.104 The neutral form of ranitidine experiences a more feeble inclusion by the CB[7] cavity than its protonated form as evident from its 1H NMR study. The nitroethylenediamine moiety in the ranitidine molecule can exhibit both E and Z isomerism and can be isolated in both forms, depending upon the counterion and the nature of the solvent.108−110 If ranitidine (both the mono- and deprotonated forms) is encapsulated inside the CB[7] cavity, the isomerism is found to be arrested through hydrogen bonding and ion–dipole interaction induced by the carbonyl groups of the CB[7] portals.104 The encapsulation of ranitidine by the CB[7] favors the Z isomer more than the E isomer (only 20% for {RH2·CB[7]}2+ and 40% E for {RH·CB[7]+}) as this form experience more favorable ion–dipole interaction which is stabilizing it.104 The CB[7] forms excellent host–guest complexes with both cationic and dicationic forms of ranitidine in aqueous environment.104 The di- and monoprotonated ranitidine forms show comparable binding constant with CB[7] as that of the cationic guest which is reported by the 1H NMR competitive binding measurement.104 The major differences between the host–guest complexation of the mono- and diprotonated forms are the preferential inclusion of different portions of the guest molecule and the orientation of the nitroethylenediamine. For the diprotonated form, both charged ends of the guest molecule are placed near to the carbonyl-rimmed portals, whereas in the monoprotonated form, the nitroethylenediamine moiety is placed a bit far from the carbonyl-rimmed portal. Moreover, it has also been studied by 1H NMR that the CB[7] protects the encapsulated ranitidine from unwanted degradation brought about by the humidity as well as acidic environment (pH 2–4) at elevated temperature.111−113 Inhibition of Neurotoxins through Host–Guest Encapsulation by CB[7] Among several neurodegenerative diseases, Parkinson’s disease (PD) is one of the common diseases characterized by a long-term disorder of the central nervous system (CNS) accompanied by tremors, stiffness in the body, and loss of body balance.114 PD probably is caused by exposure of certain neurotoxins by the dint of reactive oxygen species (ROS) and reactive nitrogen species (RNS).115 MPTP (N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, 12), a popular neurotoxin, can cause selective damage of the dopaminergic nerve cells in the substantia nigra thus inducing a PD syndrome in humans.114 In the process of degenerating neurons, MPTP gets transformed into its active species MPP+ (N-methyl-4-phenylpyridine, Figure 19) by monoamine oxidase B (MAO-B) inside the mitochondrial membrane.116 The toxic MPP+ is then captured by the dopamine transporter (DAT) and transports it into the dopamine neurons, thus increasing the production of ROS.117 As a result, there is an immediate need in the development of neuroprotective agents which can restrict the negative impact of neurotoxins in our CNS. 1H NMR spectral studies have proven perfect host–guest encapsulation of MPTP by CB[7] which is evident from the certain upfield shift (up to ∼1.0 ppm, Figure 19b-i) compared to that of the spectrum of uncomplexed MPTP (Figure 19b-ii).116 On incorporating only 0.5 equiv of CB[7], the peaks appeared to be broader along with some disappearance of resonances, which indicates the rate of exchange between the uncomplexed and CB[7]-complexed MPTP.116 Addition of 1.2 equiv of CB[7] ensures perfect host–guest encapsulation inside the CB[7] cavity inferred from the distinct upfield shift of aromatic protons, the ethylene proton in the tetrahydropyridine ring, and the methylene protons.116 The protons adjoining to the nitrogen atom experience only minimal upfield shifts, because they were located close to the carbonyl portal within the cavity.116 One of the methyl protons (H1) experiences downfield shift which was due to its position outside of the cavity nearer to the electron-dense carbonyl-laced portal.116 In fact, one of the methylene protons (H4) did not experience any significant shift upon adding CB[7], which signifies that it is located in such a position that the shielding and the deshielding effect counterbalance each other.116 On increasing the concentration of CB[7], the absorbance peak at 242 nm got attenuated accompanied by a bathochromic shift.116 The DFT study of MPTP-H+·CB[7] (Figure 20a) has also proven the same as that of the 1H NMR study with the two six-membered rings of MPTP well encapsulated inside CB[7] placing the methyl groups outside the cavity near its mouth.116 For the MPP+·CB[7] complex (Figure 20b), the DFT study is coherent with 1H NMR study for one of the lowest energies calculated aromatic ring encapsulated within the CB[7] cavity (ΔE = 1.6 kcal·mol–1).116 Mainly, three mechanisms come into the picture while talking about inhibition of neurotoxins by CB[7]. They are the following: (i) CB[7] complexation may hinder MPTP’s ability to penetrate the blood–brain barrier to show its neurotoxicity;118 (ii) even if the complex gets through the blood–brain barrier, CB[7] protects the MPTP from oxidation by MAO-B to form active MPP+ which mainly inhibits mitochondrial complex I of the electron transport chain and generates ROS;116 (iii) lastly, even if MPP+ is still formed, CB[7] restricts the transfer of MPP+ to mitochondrial complex I via DAT by mimicking a synthetic receptor.116 Thus, once again the domination of the binding constant between the guest molecule and CB[7] over their biological receptors acts a promising approach toward medicinal chemistry. (a) Molecular diagram of MPTP (12) and MPP+; (b) 1H NMR spectral graph showing the resonances of MPTP when encapsulated by (i) 1.2 equiv of CB[7], (ii) 0.5 equiv of CB[7], and (iii) free MPTP. The CB[7] and D2O protons are indicated by (●) and (○), respectively, in D2O.116 Reprinted with permission from ref (116). Copyright 2015. The American Chemical Society. Lateral view of supramolecular encapsulated (a) MPTPH+·CB[7] and (b) MPP+·CB[7] based on DFT calculation.116 Reprinted with permission from ref (116). Copyright 2015. The American Chemical Society. Relocation of Drug by Carrier Protein from the Hydrophobic Nanocavity to Its Binding Pouch—A Host Induced Guest Protonation Approach To get an insight into the molecular interaction between the supramolecular macrocycles and the drug molecule of interest, basically, two fluorescence-based approaches are present. One is using the inherent optical properties of the drug,36 and another is the use of selective fluorescent dye and studying the tuning of its photophysical properties upon interaction with a water-soluble host and the biomolecule. The second method calls for the dye to be an environment-responsive one for studying the individual binding interaction119 because they show a different fluorescence behavior in different environments. The structural characteristics of these dyes are their intramolecular charge transfer (ICT) properties, and they are composed of two basic components—an electron-rich part (donor) and an electron-deficient part (acceptor) joined by a π-conjugated spacer. They are highly polarity-dependent molecules due to extensive charge transfer. PRODAN (commonly dubbed as PRO, 13) is a small naphthalene-based ICT fluorescent dye in which 2-N,N-dimethyl amino acts as a donor and the 6-propanoyl group acts as an acceptor part (Figure 21). In pH-dependent binding studies of PRO, at basic pH (ca. 9.0), an intense fluorescence enhancement is observed along with a ∼35 nm hypsochromic effect, whereas at lower pH (<7.5), fluorescence quenching is observed. In the presence of CB[7], a significant pKa shift was observed (approximately 3.2 units) for both ground and excited states. The fluorescence-based relocation of PRO by 1,6-diamino hexane, a strong competitor of CB[7], confirms perfect encapsulation of PRO in the CB[7] cavity. UV–vis spectroscopy-based binding titration of 10 μM PRO (as above 20 μM self-aggregation occurs) with CB[7] at pH 9.0 reveals the severe diminishing effect on absorption maxima at longer wavelengths around 370 nm and a slight elevation at smaller wavelengths. The isosbestic point at around 290 nm indicates a 1:1 complex formation consistent with the cavity dimension. This fact is strongly supported by the Benesi–Hildebrand plot.120 A strong fluorescence quenching is exhibited by adding only 2.5 μM of CB[7] at pH 3.0 (Figure 22a) at 290 nm excitation, which suggests a firm binding conjoined with protonation of the PRO because of the host-induced guest protonation. The binding strength was estimated to be (2.3 ± 0.5) × 106 M–1. This fluorescence intensity can again be regenerated by displacing PRO with 1,6-diamino hexane at pH 3.0 (Figure 22b), which further supports the stronger binding of PROH+ in CB[7] than PRO. A marked increase in the fluorescence lifetime of PRO was detected in addition to the enhancement of fluorescence intensity from steady-state measurement upon encapsulation with CB[7] which experienced an alleviation of both radiative and nonradiative phenomena. The displacement of PRO in various microenvironments of host macrocycles not only shield PRO from quenching by solvent molecules but also provide a low polarizable inner cavity to PRO giving rise to both longer fluorescence lifetime and reduction of the radiative process (about 1.6 times). The anisotropy decay of the PRO·CB[7] complex is much smaller than the free PRO giving a τr value of 0.78 ns, which is shown in Figure 23a (absence of CB[7]) and Figure 23b (presence of CB[7]), which signifies a firm inclusion complex between CB[7] and PRO. Structure of PRO. (a) Fluorescence titration plot of 10 mM PRO with increasing CB[7] concentration up to 2.5 μM; (b) guest relocation assay based on fluorescence titration upon addition of 1,6-diaminohexane in the predeveloped PRO·CB[7] complex.120 Reprinted with permission from ref (120). Copyright 2016. The Royal Society of Chemistry. Fluorescence lifetime decay for (a) free and (b) PRO encapsulated CB[7]; bold lines represent the curves of best fitting. Time-resolved anisotropy decay measurement of (c) free PRO molecule and (d) CB[7]·PRO complex.120 Reprinted with permission from ref (120). Copyright 2016. The Royal Society of Chemistry. To study the displacement of PRO from the CB[7] nanocavity to the macrocyclic guest binding pouch, competitive biosupramolecular assay was executed where HSA (human serum albumin) and BSA (bovine serum albumin), a highly abundant blood protein, play the role of a stronger competitor which can knock out PRO from the CB[7] cavity very easily and bind it in its hydrophobic pocket (Figure 24a). Upon CB[7] binding, a strong attenuation of fluorescence intensity was observed when excited at 340 nm (Figure 24b) but on gradual addition of a stock solution of HSA shows an appreciable increment of fluorescence intensity (Figure 24c) followed by a 60 nm hypsochromic effect. Thus, this fluorescence activity gives an idea of a relocation phenomenon of PRO from the cavity of a drug delivery vehicle to the blood protein cavity opening a new dimension of research interest in the domain of drug carriers using CB[7] macrocycles. (a) Relocation mechanism of guest molecule PRO by competitor HSA/BSA from the CB[7] cavity; (b) fluorescence-based titration of PRO with increasing concentration of CB[7] up to 36 μM followed by subsequent incorporation of HSA in the predeveloped PRO·CB[7] complex showing a gradual increase in fluorescence intensity reaching a plateau at λex = 340 nm; (c) plot representing the fluorescence intensity against the increasing concentration of CB[7] or HSA at 520 nm for CB[7] and 470 nm for HSA, respectively.120 Reprinted with permission from ref (120). Copyright 2016. The Royal Society of Chemistry. In Vivo and In Vitro Study of Cytotoxicity of CB[7] in the Pharmaceutical Field CB[7] is increasingly in demand for several potential medicinal applications as it imparts several beneficial properties in the wide category of drug molecules, which is much needed in smart drug delivery applications. Its low cytotoxicity acts as an attribute which is motivating chemists to explore its wide variety of applications by mimicking it as a smart nanodrug carrier inside the human body. The CB[7]-induced cytotoxicity was studied by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay by incorporating it in Chinese hamster ovary (CHO-K1) cells.121 To find out the subtoxic dosage of CB[7], a wide range of concentration of CB[7] (0.1–4.5 mM) is dissolved in the cell culture incubated with CHO-K1 cells for about 48 h.121 If the concentration is above 2 mM, cell growth is found to be inhibited, whereas concentrations up to 1 mM are found to be suitable for the biological cells.121 To report the exact concentration of CB[7] that will show cytotoxic effects, a broad subtoxic range of up to 1 mM was incubated for the same period of 2 days (Figure 25a), against a control sample without CB[7], which gave an input of an IC50 value of 0.53 ± 0.02 mM.121 At concentration of 20 μM when incubated in cell culture for 48 h, the cell activity is reduced to 86 ± 7%.121 The cytotoxic effect of CB[7] was also determined within 3 h of incorporation (Figure 25b), which has assured the absence of any cytotoxicity.121 In fact, a high concentration of 1 mM of CB[7] has exhibited a tolerance level for the cells at shorter incubation periods. No detrimental effects were seen in mitochondrial activity of CHO-K1 cells stained with MitoTracker Red CMXRos when incubated with 0.5 mM of CB[7].121 Moreover, the mitochondria showed intact structure and intact membrane potential when treated with various subtoxic CB[7] concentrations. For in vivo toxicity study, the impact of a single intravenous dose of CB[7] on mice was explored at dose levels up to 300 mg kg–1.121 No cytotoxicity was observed below a 200 mg kg–1 level of dose.121 However, at elevated dose level and swift injection, the mice suffered from a shocklike state just after its administration. The highest tolerated dosage level of CB[7] was reported to be 250 mg kg–1 when the injection was pushed at a slow intravenous rate.121 All the mice injected slowly with the CB[7] began to recover after 5–8 days which signifies the removal of CB[7] from the mice bodies through either excretion or any other means. However, for oral intake the toxicity seems to be negligible in comparison with the intravenous push. Perhaps this is due to the decrease in absorption of CB[7] in the gastrointestinal tract or the lesser tendency to degrade in the oral route. Relative cell viability of CHO-K1 cells in the presence of CB[7] of concentration (0–1 mM) at different incubation times, (a) 48 h and (b) 3 h, measured using the MTT assay by examining formazan absorbance at 570 nm.121 Reprinted with permission from ref (121). Copyright 2010. The Royal Society of Chemistry. Pillararenes SDDS Based on Pillararenes: Architecture and Its Applications SDDS using pillararenes is currently a novel rapid developing arena of research due to certain interesting intrinsic features of pillararenes as a drug delivery vehicle. Pillararenes can be fabricated and functionalized very easily, and their certain attributes like immense electron richness, size adjustment, hydrophobic cavity, and single to multistimuli responsiveness can aid to develop suitable host–guest complexes, supramolecular amphiphiles with or without polymer conjugates, supramolecular vesicles, and pillararene-based polymersomes. Functionalization of pillararenes with polymeric conjugates like poly(ethylene glycol) (PEG), poly(N-isopropylacrylamide) (PNIPAM), poly(glutamamide) (PGA), and poly(caprolactone) (PCL) enhance the ability to assemble into better nanoaggregates which exhibit excellent host–guest complexation. The most fundamental SDD vehicle based on pillararenes is using it as a nanocontainer with its rim either anionically (carboxylate or phosphate) or cationically (ammonium) ionized encapsulating several oppositely charged guest molecules through electrostatic interaction.122−125 The hydrophobic inner cavity of pillararenes potentially increases water solubility and the therapeutic activity inside our biological system. The most commonly known water-soluble pillararenes are carboxylated pillar[5]arene (CP[5]) and carboxylated pillar[6]arene (CP[6]), which can easily encapsulate NHM (Figure 26) by increasing the solubility factor of NHM by 100 and reducing its cell toxicity significantly. Schematic pictogram of the chemical structure and host–guest complexation between CP[5] and NHM.126 Reprinted with permission from ref (126). Copyright 2018. The Royal Society of Chemistry. Yu, and co-workers found out that CP[6] can enhance the solubility of camptothecin (CPT) and hydroxycamptothecin (HCPT) by 380 and 40 times respectively, and their bioactivities of CPT and HCPT substantially became better as a result of the solubility enhancement.128 Tamoxifen (T), a sparingly water-soluble estrogen agonist for breast cancer treatment, also experienced the same advantage. Among the cationic charged cargoes, oxaliplatin (OxPt, 14), an anticancer drug approved by the FDA, has some limitations like low bioavailability, easy degradation before reaching the target, and lack of selectivity of tumor cells which can be easily overcome by host–guest complexation by CP[6] with high binding affinity at pH 7.4 rather than pH 5.4 (ca. 24 times higher). Thus, it can induce the sustained release of the drug in the acidic environment of the tumor (enriched with lactic acid and CO2) without any toxicity. This type of anticancer drug can be easily released (Figure 27) by a competitor guest which can knock out the desired drug from the cavity at the site of an overexpressed competitor, for example, spermine (SPM), which is a biomarker overexpressed in lungs and colorectal cancer. Schematic representation of chemotherapy based on supramolecular host–guest encapsulation between OxPt (14) and CP6.123 Reprinted with permission from ref (123). Copyright 2018. The American Chemical Society. PDT, a noninvasive and promising therapeutic approach toward cancer treatment, is often limited by severe drawbacks like dark toxicity, photobleaching effect, and hydrophobicity which can be overcome by using an amphiphilic cationic phenothiazinium molecule, methylene blue (MB, 15), encapsulated in CP[6] (Figure 28). Such encapsulation can result in a long-time ROS generation upon light irradiation responsible for killing cancer cells. Amikacin responsible for killing Gram-negative and Gram-positive bacteria has a higher MIC value which can lead to acute side effects overshadowing its potential therapeutic efficacy. Thus, CP[5] can be a promising drug delivery vehicle for tetracationic amikacin disulfate salt because of noncovalent interactions synergistically contributing toward the pillararene–amikacin complexation process. As a result, the transportation of the drug becomes smarter and more effective. Schematic diagram representing the formation of the supramolecular photosensitizer based on the host–guest complexation between CP[6] and methylene blue (15) for PDT.125 Reprinted with permission from ref (125). Copyright 2018. The Royal Society of Chemistry. Self-Assembly of Amphiphilic Pillararene Amphiphilic pillararenes are formed by changing the two mouths of each fag end of hydrophobic cores of pillararene. Ferrocenium-capped amphiphilic PA[5] can self-aggregate into cationic vesicles responsible for delivery of glutathione (GSH)-responsive drug and siRNA codelivery due to the redox-responsive cationic ferrocenium group.126 It is the first self-assembly-based SDDS (Figure 29) Representation of the fabrication of an amphiphilic PA[5] capped by ferrocene, formation of cationic vesicles, and their redox-responsive drug/siRNA release.127 Reprinted with permission from ref (127). Copyright 2014. Wiley-VCH. Single Stimuli-Responsive SDDS Based on Pillararene The different pH values of organs, tissues, inflammatory cells, and tumors provide a suitable bait for the pillararene-loaded drugs to be triggered to release at the proper site of action. Thus, this phenomenon provides an incentive to develop intrinsic pH-sensitive SDDSs featuring CP[6] and CP[5], which can rush to the tumor cells in search of an acidic microenvironment for protonating their carboxylate groups fabricated at the rims. In 2012 Huang and co-workers128 developed the first PA-based supramolecular vesicles using water-soluble pillar[6]arene (WP[6]) and a pyridine derivative, which showed a reversible interconversion between vesicles and nanotubes in varying pH environments because of the pH-responsiveness of WP[6]. Another pH-sensitive SDS was fabricated by Wang et al.129 with an alkyl chain attached with a ferrocene derivative (FcA, 16), which can efficaciously bind CP[6] in water to achieve a tadpole-like supra-amphiphile (CP[6]·FcA). This inclusion complex can further encapsulate the hydrophilic anticancer drug mitroxantrone (MTZ, 17) by curbing the toxicity that the free MTZ drug exhibits to normal cells. Although the drug-loading efficiency is too low (11.2%), it exhibited timely release at a low pH environment (Figure 30). Such application paves the way toward potential anticancer treatment. In 2017 selenium-containing PA[5] was synthesized.130 The selenoxide group adds redox responsiveness to the host–guest complexation and forms water-insoluble P[5]Se. This vesicular structure can undergo reversible disassembly/assembly process and can be used for the sustained release of DOX for anticancer therapy for about 84% in 24 h upon addition of vitamin C reducing hydrophobic selenium to hydrophilic selenide. Thus, morphological tuning is used for triggering sustained anticancer drug release. Schematic illustration of pH-sensitive SDDS constructed by complexing CP[6] and FcA (16) to form MTZ (17)-loaded supra-amphiphilic CP[6]·FcA.129 Reprinted with permission from ref (129). Copyright 2013. The American Chemical Society. Multiple Stimuli-Responsive SDDS Based on Pillararene Apart from single stimuli-responsive SDDS, rational designs to develop multistimuli-responsive drugs where response other than the pH is introduced will be a pioneering landmark in the field of drug delivery systems. Apart from pH stimuli, light stimulus is a special stimulus of interest due to its noninvasive nature, cleanliness, controllability, and rapidness.130 Azobenzene, being a famous photoresponsive molecule, finds immense application in several modern host–guest systems. Huang et al. reported supramolecular vesicles (SVs) assembled from water-soluble PA[6] and an azobenzene guest in water131 in which both UV and visible light irradiation can modulate reversible transformation between SVs and nanoparticles pertaining to the photoresponsive characteristics of the azobenzene molecule. The disulfide bond can also play the role of copartner with pH stimuli because the disulfide bond is a glutathione (GSH)-responsive group where lysine derivative (LysD) acts as a guest and dual GSH- and pH-responsive supramolecular vesicles act as a host which in turn form a strong inclusion complex. This can strongly encapsulate MTZ and exhibit its rapid release at the acidic environment of the tumor with high GSH concentration as GSH cleaves the disulfide bond.132 Thus, MTZ-packed vesicles can potentially suppress the proliferation of HepG2 cancer cells. PA[n]s modified with phosphate substituents can further enhance biocompatibility which is used to form amphiphilic host–guest complex using WP[5]P as a host and pyridinium bromide as a guest whereas hollow SVs can be prepared from WP[6]P and pyridinium bromide guest (Figure 31). Both are pH-responsive and Zn2+-responsive. The supramolecular micelle can load the hydrophobic anticancer drug doxorubicin (DOX), but the latter one can encapsulate MTZ. Saint molecules (pyridinium amphiphiles composed of one pyridinium moiety and two alkyl chains), potential vectors for intracellular delivery of DNA, and WP[6] can together form multifunctional supramolecular vesicles which are pH, Ca2+, and thermal responsive (Figure 32).135 Cationic Saint complex can cause blood clots during drug delivery, so that is why by encapsulating the Saint molecule, the pyridinium moiety get rooted inside the cavity of WP[6] that can be remodelled into anionic self-assembled vesicles by the 12-carboxylate group of WP[6]. Upon introducing Ca2+, the vesicle can undergo disruption and by increasing the temperature around 36 °C led to the generation of a large-sized vesicle which will be useful for biomimetic and bioimaging application. Thus, this host–guest complexation can easily remove all the backlogs of the Saint molecule. Novel CO2-responsive SVs can be developed from a PA[5] and an anionic surfactant, sodium dodecyl sulfonate (SDS).135 The SVs can be reversibly destroyed just by temperature treatment or by bubbling N2 to remove CO2 and again restoring upon bubbling with CO2. This is also a dual stimulus-responsive SV capable of loading the water-soluble dye Calcein. Schematic representation of the construction of the amphiphilic host–guest complex developed from WP[5]P as a host and pyridinium bromide as a guest; hollow SVs can be prepared from WP[6]P and pyridinium bromide guest.133 Reprinted with permission from ref (133). Copyright 2016. The American Chemical Society. Schematic representation of the formation of multistimuli-responsive SVs fabricated from WP[6] and Saint molecule.134 Reprinted with permission from ref (134). Copyright 2014. The American Chemical Society. Stimuli-Responsive SDDS Based on Pillararene for Dual Therapy Besides surgery, chemotherapy is also a main strategy for treating cancer, but its several side effects and drug resistance overshadow its anticancer efficacy. So, to get over these shortcomings, the so-called “combined therapy” is introduced, which includes numerous therapies like combination of chemotherapy (CT) and photodynamic therapy (PDT), photothermal therapy (PTT), or both. To investigate the benefits of combined therapy, a light-harvesting system designed with boron-dipyrromethene (BODIPY, a widely used ideal photosensitizer) modified with a quaternary ammonium derivative dye was employed as a guest to complex with CP[5].136 BODIPY has a high absorption coefficient and high ROS yield suitable for PDT.137 The complex further self-assembles into supramolecular vesicles, which firmly encapsulate the anticancer drug DOX with high loading efficiency and sustain release in acidic pH leading to the pioneering epitome of a pillararene-based supramolecular nanocarrier for effective chemo-photodynamic dual therapy. Moreover, the DOX-loaded vesicles can well localize in lysosomes and exhibit an incredible fusion of chemo- and photodynamic activities against A549 cancer cells upon irradiating with red light, highlighting the potentiality of DDS for chemo-photodynamic dual therapy. Fabrication of Stimuli-Responsive SDDS from Pillararene Based on Pro-drug Strategy In the journey of developing smart nanocarriers for drug delivery, these smart drug vehicles experienced several intrinsic drawbacks like low drug-loading capacity and premature burst release which restrict their usages. So, a pro-drug approach is used where a parent drug is connected to a macromolecule. It is pharmacologically inactive and requires enzymatic or stimuli-responsive transformation when it arrives at its target site. DOX-based pro-drugs were designed directly connecting hydrophobic DOX with a pyridinium-functionalized flexible alkyl chain or a short EGn (ethylene glycol) chain via a hydrazone bond which can easily be cleavable by acid within 30 min (Figure 33). CP[6] also catalyzes the cleaving of the hydrazine bond, thus resulting in rapid release of drug molecules under acidic conditions. This type of DOX-based supramolecular pro-drug can enter SKOV3 cancer cells by endocytosis and can lead to its inhibition verified by MTT assay. Schematic diagram of the assembly of supramolecular pro-drug nanoparticles based on CP[6] and DOX-based pro-drugs.138 Reprinted with permission from ref (139). Copyright 2015. The American Chemical Society. Multidrug resistance (MDR) is a major hurdle in the path of successful targeted drug or combination chemotherapy, so to overcome this problem, a new approach is developed toward the construction of a synergistic supramolecular drug carrier via drug–drug conjugate. This drug–drug conjugate is synthesized by taking CP[6] as a host and DOX linked with another pyridine derivative drug, isoniazide, by acid-cleavable bonds like disulfide bonds or hydrazone bonds. This obtained system shows higher drug-loading capacity and accelerated drug release along with immense stability. Construction of Pillararene-Based SDDS Using Biomolecules Tryptophan (Trp), an essential amino acid, is known to interact with DNA through the indole ring. Multiple indole rings of tryptophan can add strength to supramolecular interaction with DNA. After realizing it, Trp-modified PA[5] is synthesized.139 The supramolecular vesicle assembled by TP[5] and galactose derivative can encapsulate and carry DOX·HCl (Figure 34), which not only showed hepatoma-targeting capability to asialoglycoprotein receptor (ASGP-R) overexpressed HepG2 cells but also can overcome DOX-resistant hepatoma cells due to significant interaction between TP[5] and DOX·HCL. This is the first synergistic DNA-interacting drug nanocarrier reported to date. There are many biomolecule-based biocompatible PA[n]s like glycopillararene, mannosylated PA[5],140 and galactosylated PA[5]141 in which the latter finds its application as a host for encapsulating CPT-based pro-drug for cancer treatment. Schematic representation of the formation and drug-loading procedure of a vesicle based on Trp-modified PA[5] and a galactose derivative.142 Reprinted with permission from ref (143). Copyright 2016. The American Chemical Society. Pillararenes-Based SDDS for Treatment of Juvenile Diabetes Incorporation and delivery of biomacromolecules (enzymes and hormones) via PA[n]s SDDS is slightly problematic due to their large size, easy biodegradation, and fragility. For treatment of diabetes mellitus, smart and intelligent SDS loaded with insulin was synthesized through self-assembly of the complex between guest-modified pyridylboronic acid and WP[5] host.143 A sudden increase in glucose triggers the release of insulin due to a stronger binding reaction between cis-diol and boric acid. Later, to enhance the selectivity and sensitivity of this complex toward glucose, monoboronic acid is replaced with diphenylboronic acid bearing a long alkyl chain during guest synthesis. This supra-amphiphile can further undergo self-assembly to form vesicles which are glucose specific and can encapsulate insulin with high efficiency. These novel supramolecular vesicles showed the researchers a bright future for a potential diabetic therapy during hyperglycaemic conditions. Another type of novel insulin-loaded SV was synthesized in which a ditopic phenylboronic acid derivative containing pyrene fluorophore as a biosensor and a trimethylammonium group as a binding site with water-soluble PA[5] which can even self-assemble into vesicles was present.144 These SVs can encapsulate insulin and glucose oxidase (GOx) (Figure 35). The pyrene fluorophore stacked in a π–π fashion in the aggregated state yields excimer emission around 470 nm, allowing us to recognize it by the naked eye. When there is an increment in glucose concentration in our body, the ditopic phenylboronic acid will identify and bind glucose, resulting in the oxidation of glucose by GOx to form gluconic acid leading to a decrease in pH and evolution of H2O2. This decrease of pH stimulates the protonation of WP[5] and the rupturing of the host–guest interaction, which further collapse the SVs and release insulin. Thus, these SVs mimic a healthy pancreas and deliver insulin during the needs of the body in presence of the excess glucose. Schematic representation of a glucose-triggered supramolecular insulin transport system. (a) Chemical structure and mechanism of multiresponsiveness of diphenylboronic acid guest molecules. (b) Vesicles formed out of supramolecular self-assembly of the host–guest complex and its efficient insulin release.144 Reprinted with permission from ref (144). Copyright 2018. Wiley-VCH. Conclusion In conclusion, diverse SDDS based on CB[n] and pillararenes are elaborately reviewed in this paper. A variety of strategies are put forward in the field of biomedicine by tuning several hosts or guests which successfully meet different requirements. Nevertheless, the research areas of various CB[n] and PA[n]-based SDDS are still in infancy, and thus there are extensive scopes of solving existing problems and developing new systems to make the field of drug delivery a truly potential one. Despite many advantages, there are many bottleneck issues faced during the research with these macrocyclic drug delivery systems. Regarding CB[n]-based compounds and nanomaterials, Kim et al. showed the nontoxicity of CB[n] systems with ED50 level of more than 100 μM against human lung and ovarian cancer cells.145 Due to low solubility of CB[8], accurate determination of its toxicity level is left undetermined. Another important issue which needs to be considered before using any drug delivery containers is their cell permeability. CB[7] complexes with fluorophores conjoined with spermidine and adamantylamine were demonstrated by Isaacs et al. to be capable of crossing the cell membranes of murine macrophage cells, within 20 min, with 86% of the cells incorporated into the complex.146 Similarly, many limitations are also faced with pillarenes. High-level pillar[n]arenes (n > 7) usually do not have appreciable large-sized cavities because of structural folding and cannot be produced on a massive scale due to the uncompetitive cyclization process.147 Moreover, two functional groups need to be covalently connected para to each repeating phenylene unit, which immensely hinders their structural diversity and flexibility. In this context, it should be noted that developing smart nanomaterials for human health is one of the most important aims that chemists have studied. Therefore, implementations of controllable SDDS in practical gene/drug delivery should be a priority forever, and there is no doubt that immense progress will be achieved soon, as much successful research is going on in leaps and bounds much faster than ever predicted, and such smart SDDS will play an immense potential role in the biomedical field. Outlook Cucurbiturils and pillarenes have unique blends of various supramolecular characteristics which have prepared them to rival other conventional macrocycles in terms of flexible yet targeted drug delivery in human bodies. The arena of this research field has targeted several undiscovered treatments and cures of many deadly diseases like cancer as well as diabetes. Cucurbiturils and pillarenes have acute potential to unlock the unknown cures for many ailments due to their drug encapsulation properties. This field has immense areas yet to be cultivated and holds a handful of promises to land a revolution in the field of medicinal chemistry. Acknowledgments S.G and A.R.C thank Amity University Kolkata for infrastructural support. This work did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. The authors declare no competing financial interest. References